And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

For further information please contact: Verona P Ohtuvayre™ (ensifentrine ... prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling ...

New drug approvals and strong pipeline progress are likely to help ... it through our "Recent Price Strength" screen. Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective ...

Another pipeline program is addressing Sjogren ... largely due to product sales of Ohtuvayre. Secondly, the company’s strategic projects like Ensifentrine hold future potential for investors.

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

It should have plenty of fuel to continue growing its payout in the future. Pipeline companies tend to be excellent investments for those seeking passive income. They generate very stable revenue ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...

Verona has been assigned a unique J-code for Ohtuvayre, J7601, which took effect at the beginning of this month, the analyst tells investors in a research note. The firm believes this should ...